Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma.

Autor: Oliver-Caldes A; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.; Hospital Universitari Son Espases, IDISBA, Palma de Mallorca, Spain., Español-Rego M; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Zabaleta A; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., González-Calle V; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain., Navarro-Velázquez S; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Inogés S; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., de Cerio AL; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., Cabañas V; Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, Murcia, Spain., López-Muñoz N; Hospital Universitario 12 de Octubre, Complutense University, i+12, CNIO, Madrid, Spain., Rodríguez-Otero P; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., Reguera JL; Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), University of Sevilla, Sevilla, Spain., Moreno DF; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Martínez-Cibrian N; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., López-Corral L; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain., Pérez-Amill L; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Martin-Antonio B; Department of Experimental Hematology, Instituto de Investigación Sanitaria- Fundación Jiménez Díaz, University Autonomous of Madrid, Madrid, Spain., Rosiñol L; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Cid J; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Tovar N; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Sáez-Peñataro J; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., López-Parra M; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain., Olesti E; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Guillén E; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Varea S; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Rodríguez-Lobato LG; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Battram AM; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., González MS; Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain., Sánchez-Salinas A; Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, Murcia, Spain., González-Navarro A; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Ortiz-Maldonado V; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Delgado J; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Prósper F; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., Juan M; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Martínez-López J; Hospital Universitario 12 de Octubre, Complutense University, i+12, CNIO, Madrid, Spain., Moraleda JM; Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, University of Murcia, Murcia, Spain., Mateos MV; Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain., Urbano-Ispizua Á; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Paiva B; Clínica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, CIBER-ONC Number CB16/12/00369, Pamplona, Spain., Pascal M; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain., Fernández de Larrea C; Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 May 15; Vol. 30 (10), pp. 2085-2096.

The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.

Autor: Martínez-Cibrián N; Department of Hematology, Hospital Clínic, Barcelona, Spain., Ortiz-Maldonado V; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Español-Rego M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Department of Immunology, Hospital Clínic, Barcelona, Spain., Blázquez A; Department of Hematology, Hospital Clínic, Barcelona, Spain., Cid J; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Apheresis Unit, Hospital Clínic, Barcelona, Spain.; University of Barcelona, Barcelona, Spain., Lozano M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Apheresis Unit, Hospital Clínic, Barcelona, Spain.; University of Barcelona, Barcelona, Spain., Magnano L; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Giné E; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; CIBERONC, Madrid, Spain., Correa JG; Department of Hematology, Hospital Clínic, Barcelona, Spain., Mozas P; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Rodríguez-Lobato LG; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Rivero A; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain., Montoro-Lorite M; Department of Hematology, Hospital Clínic, Barcelona, Spain., Ayora P; Department of Hematology, Hospital Clínic, Barcelona, Spain., Navarro S; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Department of Immunology, Hospital Clínic, Barcelona, Spain., Alserawan L; Department of Immunology, Hospital Clínic, Barcelona, Spain., González-Navarro EA; Department of Immunology, Hospital Clínic, Barcelona, Spain., Castellà M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Department of Immunology, Hospital Clínic, Barcelona, Spain., Sánchez-Castañón M; Department of Immunology, Hospital Clínic, Barcelona, Spain., Cabezón R; Department of Immunology, Hospital Clínic, Barcelona, Spain., Benítez-Ribas D; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Department of Immunology, Hospital Clínic, Barcelona, Spain., Setoaín X; University of Barcelona, Barcelona, Spain.; Department of Nuclear Medicine, Hospital Clínic, Barcelona, Spain.; CIBERBBN, Madrid, Spain., Rodríguez S; Department of Radiology, Hospital Clínic, Barcelona, Spain., Brillembourg H; Department of Hematology, Hospital Clínic, Barcelona, Spain., Varea S; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Department of Clinical Pharmacology, Hospital Clínic, Barcelona, Spain., Olesti E; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; Department of Clinical Pharmacology, Hospital Clínic, Barcelona, Spain., Guillén E; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Department of Clinical Pharmacology, Hospital Clínic, Barcelona, Spain., Sáez-Peñataro J; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Department of Clinical Pharmacology, Hospital Clínic, Barcelona, Spain., de Larrea CF; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain., López-Guillermo A; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; CIBERONC, Madrid, Spain., Pascal M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Department of Immunology, Hospital Clínic, Barcelona, Spain., Urbano-Ispizua Á; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain., Juan M; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; Department of Immunology, Hospital Clínic, Barcelona, Spain.; University of Barcelona, Barcelona, Spain., Delgado J; Department of Hematology, Hospital Clínic, Barcelona, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; CIBERONC, Madrid, Spain.

Publikováno v: British journal of haematology [Br J Haematol] 2024 Feb; Vol. 204 (2), pp. 525-533. Date of Electronic Publication: 2023 Oct 31.

Economic impact of an electronic alert system to prevent venous thromboembolism in hospitalised patients

Autor: LECUMBERRI, R. ^*, PANIZO, E., GOMEZ‐GUIU, A., VAREA, S., GARCÍA‐QUETGLAS, E., SERRANO, M., GARCÍA‐MOURIZ, A., MARQUÉS, M., GÓMEZ‐OUTES, A., PÁRAMO, J.A.

Publikováno v: In Journal of Thrombosis and Haemostasis June 2011 9(6):1108-1115

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19(+) Relapsed/Refractory Malignancies

Autor: Ortíz-Maldonado V, Rives-Sola S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, Baumann T, Jordi Cid Colom, Garcia-Rey E, Llanos C, Torrebadell-Burriel M, Villamor N, Giné E, Díaz-Beyá M, Guardia L, Montoro M, Català-Temprano A, Faura A, González EA, Español-Rego M, Klein-González N, Alsina L, Castro P, Jordán-García I, Fernández S, Ramos F, Suñé G, Perpiñá U, Canals JM, Lozano M, Trias E, Scalise A, Varea S, Sáez-Peñataro J, Torres F, Calvo G, Esteve J, Urbano-Ispizua Á, Manel Juan Otero, Delgado J

Publikováno v: MOLECULAR THERAPY
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu

We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells targeting CD19) in adult and pediatric patients with relapsed/refractory CD19(+) malignancies. Patients received cyclophosphamide and fludarabine followed by ARI-000

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::48b7e20bfa9fbac5aa0d8715bb3dcfe4
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=18304

Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.

Autor: Izquierdo CP; Department of Hematology, Hospital General Universitario Gregorio Marañón (HGUGM) Madrid, Instituto de Investigación Gregorio Marañón, Madrid, Spain., Mingot-Castellano ME; Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, Seville, Spain., Fuentes AEK; Department of Hematology and Hemotherapy, Hospital La Paz, Madrid, Spain., García-Arroba Peinado J; Banc de Sang i Teixits, Hospital Universitario Joan XXIII, Tarragona, Spain., Cid J; Apheresis and Cellular Therapy Unit, Department of Hemotherapy & Hemostasis, ICMHO, IDIBAPS, Hospital Clínic de Barcelona, Barcelona, Spain., Jimenez MM; Department of Hematology, University Hospital Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona, Spain., Valcarcel D; Department of Hematology, University Hospital Vall d'Hebron, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona, Spain., Gómez-Seguí I; Department of Hematology, Hospital La Fe, Valencia, Spain., de la Rubia J; Department of Hematology, Hospital La Fe, Valencia, Spain., Martin P; Therapeutic Apheresis Unit, Hematology Department, Hospital Clínico San Carlos, Madrid, Spain., Goterris R; Hematology Service, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, Valencia, Spain., Hernández L; Hospital General Universitario de Alicante, Alicante, Spain., Tallón I; Hospital Virgen Macarena, Sevilla, Spain., Varea S; Hospital San Chinarro, Madrid, Spain., Fernández M; Hospital Universitario de A Coruña, A Coruña, Spain., García-Muñoz N; Hospital de Bellvitge, Barcelona, Spain., Vara M; Hematology Department, Hospital Universitario de Cruces, Baracaldo, Spain., Zarzoso MF; Hospital Universitario Dr. Peset, Valencia, Spain., García-Candel F; Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain., Paciello ML; Hospital Universitario 12 de Octubre, Madrid, Spain., García-García I; Hospital Universitario 12 de Octubre, Madrid, Spain., Zalba S; Hospital Universitario de Navarra, Pamplona, Spain., Campuzano V; Hospital Universitario Burgos, Burgos, Spain., Gala JM; Hospital Universitario Central de Asturias, Asturias, Spain., Estévez JV; Apheresis & Transfusion Unit, Department of Hematology & Hemotherapy, CAULE, Complejo Asistencial Universitario de León, León, Spain., Jiménez GM; Department of Hematology, Hospital Universitario Ramon y Cajal, Madrid, Spain., López Lorenzo JL; Department of Hematology Hospital Universitario Fundación Jiménez Díaz, Hematologia Madrid, Spain., Arias EG; Hospital Universitario de Villalba, Madrid, Spain., Freiría C; Hospital Universitario de Castellon, Castelló, Spain., Solé M; Hospital Universitario Juan Ramón Jiménez, Huelva, Spain., Ávila Idrovo LF; Hospital Universitario de Canarias, Tenerife, Spain., Hernández Castellet JC; Hospital Puerta del Mar, Cádiz, Spain., Cruz N; Hospital Universitario Dr. Negrín, Las Palmas, Spain., Lavilla E; Hospital Universitario Lucus Augusti, Lugo, Spain., Pérez-Montaña A; Hospital Universitario Son Espases, Palma de Mallorca, Spain., Atucha JA; Hospital de Basurto, Bilbao, Spain., Moreno Beltrán ME; Hospital Costa del Sol, Marbella, Málaga, Spain., Moreno Macías JR; Hospital Universitario de Albacete, Albacete, Spain., Salinas R; Hospital del Sagrat Cor, Universitat Internacional de Catalunya; Banc de Sang i Teixits de Catalunya, Barcelona, Spain., Del Rio-Garma J; Department of Hematology, University Hospital of Ourense, Ourense, Spain.

Publikováno v: Blood advances [Blood Adv] 2022 Dec 27; Vol. 6 (24), pp. 6219-6227.